Impact of overweight and obesity on cardiac benefit of antihypertensive treatment

E Gerdts; G de Simone; Birthe Lund; P M Okin; K Wachtell; K Boman; M S Nieminen; B Dahlöf; R B Devereux

doi:10.1016/j.numecd.2011.03.008

Impact of overweight and obesity on cardiac benefit of antihypertensive treatment

E Gerdts, G de Simone, Birthe Lund, P M Okin, K Wachtell, K Boman, M S Nieminen, B Dahlöf, R B Devereux

26 Citationer (Scopus)

Abstrakt

BACKGROUND AND AIMS: Increased body mass index (BMI) has been associated with increased cardiovascular morbidity and mortality in hypertension. Less is known about the impact of BMI on improvement in left ventricular (LV) structure and function during antihypertensive treatment. METHODS AND RESULTS: Annual BMI, echocardiograms and cardiovascular events were recorded in 875 hypertensive patients with LV hypertrophy during 4.8 years randomized treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy. Patients were grouped by baseline BMI into normal (n = 282), overweight (n = 405), obese (n = 150) and severely obese groups (n = 38) (BMI ≤24.9, 25.0-29.9, 30.0-34.9, and ≥35.0 kg/m(2), respectively). At study end, residual LV hypertrophy was present in 54% of obese and 79% of severely obese patients compared to 31% of normal weight patients (both p

Originalsprog	Engelsk
Tidsskrift	Nutrition, Metabolism & Cardiovascular Diseases
Vol/bind	23
Udgave nummer	2
Sider (fra-til)	122-129
ISSN	0939-4753
DOI	https://doi.org/10.1016/j.numecd.2011.03.008
Status	Udgivet - 2013

Adgang til dokumentet

10.1016/j.numecd.2011.03.008

Citationsformater

@article{4e770e5d6c69419c8b208e3113bd2dfd,

title = "Impact of overweight and obesity on cardiac benefit of antihypertensive treatment",

abstract = "BACKGROUND AND AIMS: Increased body mass index (BMI) has been associated with increased cardiovascular morbidity and mortality in hypertension. Less is known about the impact of BMI on improvement in left ventricular (LV) structure and function during antihypertensive treatment. METHODS AND RESULTS: Annual BMI, echocardiograms and cardiovascular events were recorded in 875 hypertensive patients with LV hypertrophy during 4.8 years randomized treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy. Patients were grouped by baseline BMI into normal (n = 282), overweight (n = 405), obese (n = 150) and severely obese groups (n = 38) (BMI ≤24.9, 25.0-29.9, 30.0-34.9, and ≥35.0 kg/m(2), respectively). At study end, residual LV hypertrophy was present in 54% of obese and 79% of severely obese patients compared to 31% of normal weight patients (both p ",

author = "E Gerdts and {de Simone}, G and Birthe Lund and Okin, {P M} and K Wachtell and K Boman and Nieminen, {M S} and B Dahl{\"o}f and Devereux, {R B}",

year = "2013",

doi = "10.1016/j.numecd.2011.03.008",

language = "English",

volume = "23",

pages = "122--129",

journal = "Nutrition, Metabolism and Cardiovascular Diseases",

issn = "0939-4753",

publisher = "Elsevier Ltd",

number = "2",

}

TY - JOUR

T1 - Impact of overweight and obesity on cardiac benefit of antihypertensive treatment

AU - Gerdts, E

AU - de Simone, G

AU - Lund, Birthe

AU - Okin, P M

AU - Wachtell, K

AU - Boman, K

AU - Nieminen, M S

AU - Dahlöf, B

AU - Devereux, R B

PY - 2013

Y1 - 2013

N2 - BACKGROUND AND AIMS: Increased body mass index (BMI) has been associated with increased cardiovascular morbidity and mortality in hypertension. Less is known about the impact of BMI on improvement in left ventricular (LV) structure and function during antihypertensive treatment. METHODS AND RESULTS: Annual BMI, echocardiograms and cardiovascular events were recorded in 875 hypertensive patients with LV hypertrophy during 4.8 years randomized treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy. Patients were grouped by baseline BMI into normal (n = 282), overweight (n = 405), obese (n = 150) and severely obese groups (n = 38) (BMI ≤24.9, 25.0-29.9, 30.0-34.9, and ≥35.0 kg/m(2), respectively). At study end, residual LV hypertrophy was present in 54% of obese and 79% of severely obese patients compared to 31% of normal weight patients (both p

AB - BACKGROUND AND AIMS: Increased body mass index (BMI) has been associated with increased cardiovascular morbidity and mortality in hypertension. Less is known about the impact of BMI on improvement in left ventricular (LV) structure and function during antihypertensive treatment. METHODS AND RESULTS: Annual BMI, echocardiograms and cardiovascular events were recorded in 875 hypertensive patients with LV hypertrophy during 4.8 years randomized treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy. Patients were grouped by baseline BMI into normal (n = 282), overweight (n = 405), obese (n = 150) and severely obese groups (n = 38) (BMI ≤24.9, 25.0-29.9, 30.0-34.9, and ≥35.0 kg/m(2), respectively). At study end, residual LV hypertrophy was present in 54% of obese and 79% of severely obese patients compared to 31% of normal weight patients (both p

U2 - 10.1016/j.numecd.2011.03.008

DO - 10.1016/j.numecd.2011.03.008

M3 - Journal article

C2 - 21775111

VL - 23

SP - 122

EP - 129

JO - Nutrition, Metabolism and Cardiovascular Diseases

JF - Nutrition, Metabolism and Cardiovascular Diseases

SN - 0939-4753

IS - 2

ER -

Impact of overweight and obesity on cardiac benefit of antihypertensive treatment

Abstrakt

Adgang til dokumentet

Fingeraftryk

Citationsformater